Citations

Showing 10 of 108162 citations.

Addressing the Maintenance of Certification Challenge: The College of American Pathologists Response
Hammond, M. Elizabeth H. , Filling, Constance M., Neumann, Ann, Homburger, Henry A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 5 | Pages: 666-675

10.5858/2005-129-0666-atmocc | PMID 15859640 Get It

Abstract Context. —The American Board of Medical Specialties Maintenance of Certification (MOC) process will become effective in 2006. The College of American Pathologists (CAP) Education Committee defined pathology-specific competencies within MOC categories and used data from a survey of pathologists to create education courses targeted to each MOC category. Objective. —To define pathology-specific competencies within MOC categories and to identify priority learning needs for pathologists. Design. —A 5-step process was completed for defining pathology-specific competencies within MOC categories and creating education courses targeted to competencies identified in each MOC category. A random survey was distributed to identify priority learning needs based on the gap between the importance rating of each knowledge and skill statement and a rating of current level of proficiency in 3 areas. Results. —Specific competencies and knowledge and skill statements were identified for each MOC competency category. Findings indicate pathologists believe they are poorly prepared for practice in competency categories related to systems-based practice and practice-based learning and improvement. Conclusions. —The CAP has focused education efforts on identifying a process for defining and responding to the MOC challenge. Pathologists have told us that they have significant needs for learning in specified areas and the CAP will focus development of education courses to meet those identified needs.
Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply
Wadström, Karin , Jacobsson, L. , Mohammad, Aladdin J , Warrington, Kenneth J. , Matteson, Eric L. , Turesson, Carl , Jacobsson, Lennart , Warrington, Kenneth J , Mohammad, Aladdin J , Turesson, Carl

Mayo Clinic

Rheumatology | February 10, 2021 | Volume: 60 | Issue: 7 | Pages: e262-e263

10.1093/rheumatology/keab143 | PMID 33576780 Get It

Pathologic Quiz Case: A 33-Year-Old Woman With a Large Temporal Mass
McFadden, Kathryn , Unni, K. Krishnan, Couce, Marta , Ionescu, Diana N.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 4 | Pages: 539-540

10.5858/2005-129-539-pqcayw | PMID 15794684 Get It

Survival and Glycemic Control in Patients With co-existing Squamous Cell Carcinoma and Diabetes Mellitus
Ederaine, Sophia A. , Dominguez, Johanny Lopez , Harvey, Jamison A. , Mangold, Aaron R. , Coppola, Kyle , Karlin, Nina J. , Cook, Curtiss B. , Karlin, Nina J , Mangold, A R , Dominguez, Johanny L , Kosiorek, Heidi , Buras, Matthew

Mayo Clinic

Future Science OA | February 10, 2021 | Volume: 7 | Issue: 5 | Pages: No page available

10.2144/fsoa-2020-0150 | PMID 34046188 Get It

Patient Safety in Anatomic Pathology: Measuring Discrepancy Frequencies and Causes
Raab, Stephen S., Nakhleh, Raouf E. , Ruby, Stephen G.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 4 | Pages: 459-466

10.5858/2005-129-459-psiapm | PMID 15794667 Get It

Abstract Context.—Anatomic pathology discrepancy frequencies have not been rigorously studied. Objective.—To determine the frequency of anatomic pathology discrepancies and the causes of these discrepancies. Design.—Participants in the College of American Pathologists Q-Probes program self-reported the number of anatomic pathology discrepancies in their laboratories by prospectively performing secondary review (post–sign-out) of 100 surgical pathology or cytology specimens. Reasons for the secondary review included conferences, external review, internal quality assurance policy, and physician request. Participants.—Seventy-four laboratories self-reported data. Main Outcome Measures.—Frequency of anatomic pathology discrepancy; type of discrepancy (ie, change in margin status, change in diagnosis, change in patient information, or typographic error); effect of discrepancy on patient outcome (ie, no harm, near miss, or harm); and clarity of report. Results.—The mean and median laboratory discrepancy frequencies were 6.7% and 5.1%, respectively. Forty-eight percent of all discrepancies were due to a change within the same category of interpretation (eg, 1 tumor type was changed to another tumor type). Twenty-one percent of all discrepancies were due to a change across categories of interpretation (eg, a benign diagnosis was changed to a malignant diagnosis). Although the majority of discrepancies had no effect on patient care, 5.3% had a moderate or marked effect on patient care. Conclusions.—This study establishes a mean multi-institutional discrepancy frequency (related to secondary review) of 6.7%.
Testing for Defective DNA Mismatch Repair in Colorectal Carcinoma: A Practical Guide
Burgart, Lawrence J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 11 | Pages: 1385-1389

10.5858/2005-129-1385-tfddmr | PMID 16253016 Get It

Abstract Context. —Significant bench and clinical data have been generated during the last decade regarding DNA mismatch repair in colorectal carcinoma. Objectives. —To review clinically relevant aspects of defective DNA mismatch repair in colorectal carcinoma and to suggest testing algorithms for identification of these tumors in the sporadic and familial settings. Data Sources. —This article is based on literature review and clinical testing experience of more than 2000 patient samples. Conclusions. —Approximately 15% of colorectal carcinomas arise as a result of defective DNA mismatch repair. Ninety percent of these carcinomas are sporadic, arising as a result of methylation of the MLH1 gene promoter, silencing expression. These sporadic carcinomas have improved stage-specific prognosis and can be identified by demonstrating aberrant loss of expression with an MLH1 immunoperoxidase stain. Familial colorectal carcinomas with defective DNA mismatch repair (Lynch syndrome) are due to a germline defect in one of several DNA mismatch repair genes. The familial carcinomas are best identified with a combination of immunohistochemistry and molecular microsatellite analysis. This testing facilitates subsequent directed genetic testing of the proband and family members.
Sudden Unexpected Death in a 31-Year-Old Man Caused by Arrhythmogenic Right Ventricular Cardiomyopathy
Ye, Dongjiu, Edwards, William D. , Rizkalla, Waheeb

Mayo Clinic

Archives of Pathology and Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 10 | Pages: 1330-1333

10.5858/2005-129-1330-sudiay | PMID 16196526 Get It

Abstract A 31-year-old white man collapsed suddenly at a graduation ceremony and was pronounced dead after attempted resuscitation. He had no pertinent medical or familial history. Postmortem toxicologic studies showed negative results. A complete autopsy revealed a cardiac cause of death. Grossly, the right ventricular chamber was moderately to markedly dilated, and its free wall showed extensive myocardial adiposity. Microscopically, the right ventricular free wall consisted predominantly of adipose tissue, with only small subendocardial islands of hypertrophied myocytes and interstitial fibrosis. These features are characteristic of arrhythmogenic right ventricular cardiomyopathy. Moreover, Purkinje-like cells were observed among right ventricular myocytes and may have increased the likelihood of developing an arrhythmia. To our knowledge, this finding has not been previously emphasized. Because arrhythmogenic right ventricular cardiomyopathy accounts for 10% of cases of sudden unexpected cardiac death, recognition of this disease by pathologists is important, especially in cases of otherwise unexplained death in young persons.
Granular Cell Tumor: Immunohistochemical Assessment of Inhibin-α, Protein Gene Product 9.5, S100 Protein, CD68, and Ki-67 Proliferative Index With Clinical Correlation
Boyer, Philip J. , Lewis, Jean E., Kapadia, Silloo B., Le, Brian Huong Canh

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 7 | Pages: 771-775

10.5858/2004-128-771-gctiao | PMID 15214825 Get It

Abstract Context.—Granular cell tumor (GCT) is a rare tumor of nerve sheath origin with a predilection for upper aerodigestive tract, skin, and soft tissue. The neoplastic cells typically express S100 and CD68 (KP-1), the latter due to cytoplasmic lysosome content. However, the histogenesis of this tumor is unknown. Additionally, distinction between benign and malignant GCT is difficult because of histologic similarity and lack of reliable criteria that can predict clinical behavior. Objective.—To perform a comparative, side-by-side immunohistochemical assessment of the traditional immunohistochemical markers for GCTs (S100, CD68), along with the newer markers (inhibin-α, protein gene product 9.5) for these tumors. Design.—To address diagnostic and prognostic issues, we studied 30 specimens of GCT (27 primary and 3 recurrent tumors, 2 of which occurred consecutively in the same patient) for (1) nuclear pleomorphism, prominent nucleoli, necrosis, spindling, high nuclear-cytoplasmic ratio, and mitoses; (2) immunohistochemical expression of inhibin-α, protein gene product 9.5, S100, CD68 (KP-1), and Ki-67 using the avidin-biotin complex method on formalin-fixed, paraffin-embedded sections; and (3) correlation between tumor grade, proliferative fraction, and clinical data. Results.—Twenty-seven of 27 primary GCTs and 1 of 3 recurrent GCTs had typical histologic features, while the 2 consecutive recurrent GCT specimens from the same patient were atypical (moderate nuclear atypia and prominent nucleoli alone). The mean age for primary GCT was 37.3 years (range, 5–67 years), and mean size was 1.89 cm. None of the cases metastasized. All 30 specimens showed diffuse (2+ to 3+) staining for S100, CD68, and inhibin-α, and 3+ staining for protein gene product 9.5; pseudoepitheliomatous hyperplasia was nonreactive. The Ki-67 proliferative index was less than 1% to 20% in typical nonrecurrent cases, 1% in the typical recurrent case, and 1% and 10% in 2 sequential recurrences of the atypical case. Conclusion.—Our study expands the immunophenotype of GCT (S100, CD68, protein gene product 9.5, and inhibin-α) regardless of location and supports a neural origin. Intensity of immunohistochemical staining had no prognostic significance. Although 1 of the 2 recurrent GCTs had atypical features, the Ki-67 proliferative index did not distinguish reliably between typical (nonrecurrent) and atypical or recurrent GCTs. The significance of inhibin expression with regard to cell differentiation and pathogenesis is unclear and warrants further investigation.
Mind the Quality Gap When Banking on Dry Blood Spots
Carpentieri, David , Colvard, Amber, Petersen, Jackie, Marsh, William, David‐Dirgo, Victoria , Huentelman, Matt , Pirrotte, Patrick , Sivakumaran, Theru A. , Carpentieri, David

Mayo Clinic

Biopreservation and Biobanking | February 10, 2021 | Volume: 19 | Issue: 2 | Pages: 136-142

10.1089/bio.2020.0131 | PMID 33567235 Get It

Dry blood spots (DBS) offer many advantages over other blood banking protocols due to the reduction of time and equipment needed for collection and the ease of processing, storage, and shipment. In addition, the sample size makes it a very attractive method when considering the banking of small pediatric samples. On that note, the Centers for Disease Control and Prevention (CDC) preanalytical standards for DBS are commonly used in the worldwide mass spectrometry-based inborn errors of metabolism screening programs. However, these guidelines may not apply for analytes and protocols not included in these programs. In fact, the availability of leftover samples and the ongoing interest in protocols outside this scenario are providing us with new DBS biobanking insights. Herein, we review the literature for indicators that should be considered in the design of prospective fit for purpose DBS biobanks, especially for those focused mostly on pediatric and OMIC platforms.
Continuous Monitoring of Stat and Routine Outlier Turnaround Times: Two College of American Pathologists Q-Tracks Monitors in 291 Hospitals
Novis, David A., Dale, Jane C., Howanitz, Peter J., Walsh, Molly K.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 6 | Pages: 621-626

10.5858/2004-128-621-cmosar | PMID 15163240 Get It

Abstract Context. —The laboratory test turnaround times (TATs) that exceed the expectations of clinicians who order those tests, the so-called outlier test reporting rates, may be responsible for perceptions of inadequate laboratory service. Objective. —To monitor outlier test reporting rates for emergency department stat potassium results and routine inpatient morning blood tests. Design. —In 2 different monitors, each conducted for 2 years, laboratory personnel in institutions enrolled in the College of American Pathologists (CAP) Q-Tracks program tracked the percentages of emergency department stat potassium results and/or the percentages of morning rounds routine test results that were reported later than self-imposed reporting deadlines. Setting. —A total of 291 hospitals participating in 2 CAP Q-Tracks monitors. Results. —Participants monitored 225 140 stat emergency department potassium TATs, of which 33 402 (14.8%) were outliers, and 1 055 040 routine morning test reporting times, of which 123 554 (11.7%) were outliers. For both monitors, there was a significant ( P < .05) downward trend in the outlier rates as the number of quarters in which participants submitted data increased. Conclusion. —Outlier reporting rates for emergency department stat potassium and routine morning test results decreased during the 2-year period of continuous monitoring. The CAP Q-Tracks program provides an effective vehicle by which providers of laboratory services may improve the timeliness with which they deliver the results of laboratory tests.